Previous Close | 0.1900 |
Open | 0.4500 |
Bid | 0.0000 |
Ask | 0.5000 |
Strike | 65.00 |
Expire Date | 2024-05-17 |
Day's Range | 0.1900 - 6.3300 |
Contract Range | N/A |
Volume | |
Open Interest | 14 |
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.